

Baxter International Inc.
Key Product Line Sales
Period Ending December 31, 2002
(Unaudited)

(\$ in Millions)	Q1 2002	% growth	Q2 2002	% growth	Q3 2002	% growth	Q4 2002	% growth	FY 2002	% growth
BioScience										
Recombinant	232	31%	247	28%	255	29%	265	11%	999	24%
Plasma Proteins ¹	238	9%	241	(9%)	251	(3%)	278	(0%)	1,008	(1%)
Antibody Therapy	76	5%	73	(13%)	83	1%	86	(5%)	318	(3%)
Transfusion Therapies ²	130	9%	131	5%	130	(1%)	157	(8%)	549	0%
Medication Delivery										
IV Therapy ³	223	(1%)	240	5%	244	7%	275	12%	982	6%
Drug Delivery	132	21%	134	17%	147	34%	167	23%	580	24%
Electronic Infusion Systems	151	0%	163	1%	168	(1%)	214	4%	696	2%
Anesthesia	121	(3%)	162	17%	152	8%	194	22%	629	12%
Renal										
PD Therapy	300	3%	304	1%	325	6%	333	3%	1,262	3%
HD Therapy	97	(5%)	99	(5%)	106	(4%)	116	5%	418	(2%)

¹ Excludes Antibody Therapy. Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, bioSurgery and other plasma-based products

² Formerly referred to as Fenwal